Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (1941)	3/5/1999 1:40:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Don, No, a suit against a manufacturer wouldn't get anywhere. The drug interactions (which are the only things that could produce a suit) are known and disclosed. An individual doctor who prescribed a drug with more serious side effects might conceivably be at risk, though. Haven't heard of any such suits. Peter

To: Don Miller who wrote (1941)	3/5/1999 2:52:00 PM
From: David Howe	Read Replies (3) \| Respond to of 10280

Yes, they could be liable, or at least vulnerable to a lawsuit. I suspect that some of the original manufacturers will pull the original product from production once the ICE is available. The FDA required that Seldane sales be halted, so that could also apply. Some of the products that SEPR has ICE's for have black labels / warnings already. Regarding JNJ. IMO most of us would be very unhappy if SEPR was bought out at 155 or anywhere close to that price. Dave